Journal Watch · Science Translational Medicine · 2026

Murine autoantigen-specific type 1 regulatory T cells promote oligodendrogenesis through amphiregulin-EGFR signaling.

Together, these results indicate that antigen-specific regulatory T cells can promote oligodendrogenesis and highlight the amphiregulin-oligodendrocyte EGFR pathway as a target for therapeutic intervention in MS.

Clarke R, Rayatpour A, Garnica J et al.Science Translational Medicine3 min readPharma relevance 60/100

DOI: 10.1126/scitranslmed.aef2269PMID: 42455897Study type: preclinical (animal / model) study

TL;DR

Together, these results indicate that antigen-specific regulatory T cells can promote oligodendrogenesis and highlight the amphiregulin-oligodendrocyte EGFR pathway as a target for therapeutic intervention in MS.

Key findings

  • These findings indicate that the oligodendrocyte-mediated therapeutic effects of pMHCII-NP treatment are dissociated from the anti-inflammatory properties of Tr1 cells; instead, they involve Tr1 cell-derived Areg to activate oligodendrocytes in an EGFR-dependent manner.
  • Together, these results indicate that antigen-specific regulatory T cells can promote oligodendrogenesis and highlight the amphiregulin-oligodendrocyte EGFR pathway as a target for therapeutic intervention in MS.

What they did

By investigating the effects of pMHCII-NP therapy on focal demyelinated lesions in the spinal cord induced by lysolecithin and sustained by chronic autoimmune encephalitogenic insults, here, we show that CNS antigen-specific Tr1 cells promote oligodendrogenesis, the preservation of axon caliber, and remyelination. Cell-specific deletion of <i>amphiregulin</i> (<i>Areg</i>) in T cells or of the <i>epidermal growth factor receptor</i> (<i>Egfr</i>) in oligodendrocytes abrogated these therapeutic outcomes. Oligodendrocyte-specific deletion of <i>Egfr</i> did not impair the pharmacodynamic or anti-inflammatory effects of pMHCII-NP treatment.

Full abstract (original)

Background: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that results from oligodendrocyte loss and multifocal demyelination of the CNS white matter. Current therapies can suppress the progression of CNS inflammation but do not actively promote tissue repair. Nanoparticles (NPs) coated with CNS-specific peptide-major histocompatibility complex class II (pMHCII) molecules can alleviate disability in mice with experimental autoimmune encephalomyelitis (EAE) by triggering the formation, expansion, and recruitment of antigen-specific type 1 regulatory CD4<sup>+</sup> T cells (Tr1 cells).

What they did: By investigating the effects of pMHCII-NP therapy on focal demyelinated lesions in the spinal cord induced by lysolecithin and sustained by chronic autoimmune encephalitogenic insults, here, we show that CNS antigen-specific Tr1 cells promote oligodendrogenesis, the preservation of axon caliber, and remyelination. Cell-specific deletion of <i>amphiregulin</i> (<i>Areg</i>) in T cells or of the <i>epidermal growth factor receptor</i> (<i>Egfr</i>) in oligodendrocytes abrogated these therapeutic outcomes. Oligodendrocyte-specific deletion of <i>Egfr</i> did not impair the pharmacodynamic or anti-inflammatory effects of pMHCII-NP treatment.

Results & conclusions: These findings indicate that the oligodendrocyte-mediated therapeutic effects of pMHCII-NP treatment are dissociated from the anti-inflammatory properties of Tr1 cells; instead, they involve Tr1 cell-derived Areg to activate oligodendrocytes in an EGFR-dependent manner. Together, these results indicate that antigen-specific regulatory T cells can promote oligodendrogenesis and highlight the amphiregulin-oligodendrocyte EGFR pathway as a target for therapeutic intervention in MS.

Abstract © the authors / Science Translational Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1126/scitranslmed.aef2269 · PubMed 42455897.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Science Translational Medicine study find?

Together, these results indicate that antigen-specific regulatory T cells can promote oligodendrogenesis and highlight the amphiregulin-oligodendrocyte EGFR pathway as a target for therapeutic intervention in MS.

What type of study is this?

It is a preclinical (animal / model) study, published in Science Translational Medicine in 2026. By investigating the effects of pMHCII-NP therapy on focal demyelinated lesions in the spinal cord induced by lysolecithin and sustained by chronic autoimmune encephalitogenic insults, here, we show that CNS antigen-specific Tr1 cells promote oligodendrogenesis, the preservation of axon caliber, and remyelination.

Where can I read the original paper?

The original is at the publisher via DOI 10.1126/scitranslmed.aef2269. PubMed ID: 42455897. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Clarke R, Rayatpour A, Garnica J et al.. Murine autoantigen-specific type 1 regulatory T cells promote oligodendrogenesis through amphiregulin-EGFR signaling.. Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.aef2269.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/murine-autoantigen-specific-type-1-regulatory-t-cells-promote-oligodendr-ef2269/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides